Delivery Order SPE2DR25D3103-SPE2DR26F0B2L
- Not listed
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ganirelix Acetate 250 micrograms/0.5 milliliters in 0.5-milliliter units, with a ceiling value of $3,202.64 and an ultimate completion date of August 22, 2025. This non-set-aside contract represents a routine pharmaceutical procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,318.16 for Ganirelix Acetate 250 micrograms/0.5 milliliters on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The product is a gonadotropin-releasing hormone antagonist used in fertility treatment...
- The Defense Logistics Agency awarded a delivery order valued at $3,152.51 to AmerisourceBergen Drug Corp for the supply of Ganirelix Acetate 250 mcg/0.5 mL injection on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-competitive, firm fixed-price delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $20,718.28 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division for the supply of 4,565,662,809 units of the pharmaceutical product Ganirelix Acetate 250 mcg/0.5 mL. This contract does not have a set-aside designation and has a completion date of September 4, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal contracts and indefinite...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GANIRELIX ACET 250 MCG/0.5 ML 0.5ML, a pharmaceutical product, with a ceiling value of $11,614.06. The contract is a firm fixed-price, delivery order contract with a period of performance through March 17, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GANIRELIX ACET 250 MCG/0.5 ML 0.5ML, a pharmaceutical product. The contract has a ceiling value of $5,566.28 and a completion date of March 18, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,058.04, is for the delivery of the drug Ganirelix Acetate 250 MCG/0.5 ML 0.5ML. It has an ultimate completion date of December 11, 2024. This contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,506.80 firm fixed-price delivery order is for the supply of 4,566,559,881 units of the drug Ganirelix Acetate 250 mcg/0.5 mL. The contract has an ultimate completion date of November 29, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- On July 22, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $40,816.93 to AmerisourceBergen Drug Corp for GONAL-F RFF REDI-JECT 900 UNIT 1.44ML pharmaceutical products. This firm fixed-price, non-set-aside delivery order is scheduled for completion by July 23, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $28,981.54 delivery order to AmerisourceBergen Drug Corp for GONAL-F RFF Redi-Ject 900 Unit 1.44ML, a pharmaceutical product for federal medical supply needs. This competitively awarded, firm fixed price delivery order is scheduled for completion by December 8, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F0B2LDelivery Order
On February 3, 2026, the Defense Logistics Agency awarded a delivery order valued at $3,540.22 to Amerisourcebergen Drug Corp for the supply of Ganirelix Acetate 250 micrograms/0.5 milliliters in 0.5-milliliter units. This firm fixed-price delivery order is scheduled for completion by February 4, 2026, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation. Amerisourcebergen Drug Corp, a subsidiary of parent company Cencora, Inc., serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under Amerisourcebergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The contract supports critical medical needs for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 2/2/26 |